Notch
Notch signaling is evolutionarily conserved and operates in many cell types and at various stages during development. Notch signaling occurs via cell-cell communication, where transmembrane ligands on one cell activate transmembrane receptors on a juxtaposed cell.
Regulation of Notch signaling is critical to development and maintenance of most eukaryotic organisms. The Notch receptors (NOTCH1, 2, 3, and 4) and ligands (DLL1, 3, and 4, JAG1 and 2) are integral membrane proteins and direct cell-cell interactions are needed to activate signaling. Ligand-expressing cells activate Notch signaling through an unusual mechanism involving Notch proteolysis to release the intracellular domain from the membrane, allowing the Notch receptor to function directly as the downstream signal transducer.
All Product Categories
-
Notch Related Products (123)
Related Products (123)
-
Recombinant Proteins (52)
-
Antibodies (12)
-
PUMAi
0 ImagesCat. No.: HY-167182CAS No.: 470695-03-5PUMAi is a PUMA inhibitor that disrupts the interaction between PUMA and BCL-xL. PUMAi inhibits apoptosis, caspase-3 activation, WNT/NOTCH pathway activation, and DNA damage. PUMAi protects intestinal tissues in mice, promotes the growth of colonoids, and reduces chemotherapy-induced weight loss, gastrointestinal damage, and lethality. PUMAi alleviates acetaminophen-induced liver injury and cytoplasmic translocation of HMGB1 in mice. PUMAi can be used in studies related to gastrointestinal injury, intestinal injury, and liver injury.
-
Anti-NOTCH1 Antibody
0 ImagesCat. No.: HY-P990476Purity: 98.67%The Anti-NOTCH1 Antibody is a CHO-expressed human antibody targeting NOTCH1. The Anti-NOTCH1 Antibody has a huIgG2 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 144.7 kDa. The isotype control for the Anti-NOTCH1 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
-
Hexamethylene bisacetamide (Standard)
0 ImagesSynonyms: HMBA (Standard)Hexamethylene bisacetamide (Standard) is the analytical standard of Hexamethylene bisacetamide. This product is intended for research and analytical applications. Hexamethylene bisacetamide (HMBA) is a differentiation inducer and selective bromine domain inhibitor that can differentiate across the blood-brain barrier. Hexamethylene bisacetamide can induce tumor cell differentiation and inhibit cell proliferation, showing antitumor activity. Hexamethylene bisacetamide induces apoptosis by Notch1, Bcl-2 and p53 signaling pathways. In addition, Hexamethylene bisacetamide improves the obesity phenotype of mice.
